Finotonlimab injection | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Company: Sinocelltech Ltd.
Medicine type: Biologic
Therapeutic area: Oncology
Indications recorded in the public source: Head and neck squamous cell carcinoma: with platinum-based chemotherapy as first-line treatment of recurrent and/or metastatic disease. Hepatocellular carcinoma: with bevacizumab for unresectable or metastatic disease without previous systemic treatment.
Indication source and scope: Source date(s): 2025. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label. Additional indications may be supported by newer announcements or submissions rather than the older full label; see the indication sources.
Prescribing-information limitations: Indications checked against an official public submission. The full original prescribing information is still unavailable.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Market-by-market verification pending.
Insurance classification: Included in national insurance (Category B)
Insurance edition: 2025 edition; effective 1 January 2026
Insurance restrictions: Restricted to: (1) first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma; (2) use with bevacizumab for unresectable or metastatic hepatocellular carcinoma without previous systemic treatment.
Insurance period: 2026-01-01 to 2027-12-31
Insurance verification notes: Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

Sources

Open the interactive record, public price references and discussions